Topics

Latest "Pharmaceutical Executive Conferences website" News Stories - Page: 4

18:02 EDT 21st September 2019 | BioPortfolio

Here are the most relevant search results for "Pharmaceutical Executive Conferences website" found in our extensive news archives from over 250 global news sources.

More Information about Pharmaceutical Executive Conferences website on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Pharmaceutical Executive Conferences website for you to read. Along with our medical data and news we also list Pharmaceutical Executive Conferences website Clinical Trials, which are updated daily. BioPortfolio also has a large database of Pharmaceutical Executive Conferences website Companies for you to search.

Showing "Pharmaceutical Executive Conferences website" News Articles 76–100 of 16,000+

Friday 20th September 2019

Premature Ejaculation Pipeline Drugs and Companies, Q2 2019 [Published by VPA Research] Prices from USD $1799

Summary Premature Ejaculation pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Premature Ejaculation RD activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.Extensive Coverage of Pipeline CandidatesThe Premature Ejaculation report covers al...


2019 Bone Degeneration Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Bone Degeneration Clinical Trials Study provides complete list of trials completed, ongoing and planned for Bone Degeneration. It presents indepth analysis of Bone Degeneration clinical trials across markets and companies. The research work is for providing complete understanding into trends in Bone Degeneration. The report covers a key snapshot of trial tren...

Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson's disease in Japan

DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): Regulatory Approval 20.09.2019 / 17:31 The issuer is solely responsible for the content of this announcement. Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson's disease in Japan Milan, Italy, September 20, 2019 - Newron Pharmaceuticals S.p...


2019 Persistant Allergic Rhinitis Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Persistant Allergic Rhinitis Clinical Trials Study provides complete list of trials completed, ongoing and planned for Persistant Allergic Rhinitis. It presents indepth analysis of Persistant Allergic Rhinitis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Persistant Allergic Rhinitis. Th...

2019 Behcet Disease Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Behcet Disease Clinical Trials Study provides complete list of trials completed, ongoing and planned for Behcet Disease. It presents indepth analysis of Behcet Disease clinical trials across markets and companies. The research work is for providing complete understanding into trends in Behcet Disease. The report covers a key snapshot of trial trends, enrollme...

 Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)

Results from a matching-adjusted indirect comparison (MAIC) suggest that cabozantinib provides two additional months of progression-free survival versus regorafenib in the second-line treatment of advanced hepatocellular carcinoma1 Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus...

Advicenne to Present Eight Posters on the Positive Results of ADV7103 in the Treatment of Rare Nephrological Diseases at Major International Conferences

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for...

2019 Hemophagocytic Lymphohistiocytosis Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Hemophagocytic Lymphohistiocytosis Clinical Trials Study provides complete list of trials completed, ongoing and planned for Hemophagocytic Lymphohistiocytosis. It presents indepth analysis of Hemophagocytic Lymphohistiocytosis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Hemophagocytic...

Newron Pharmaceuticals: Commercialization Partner Meiji Seika Together with Eisai Announce the Approval of Safinamide for Parkinson’s Disease in Japan

Newron Pharmaceuticals S.pA. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to note its partner Meiji Seika Pharma Co., Ltd., together with Eisai Co., Ltd., have announced the manufacturing and marketing approval in Japan for Equfina® TABLETS (safinamide mesi...

2019 Bronchiectasis Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Bronchiectasis Clinical Trials Study provides complete list of trials completed, ongoing and planned for Bronchiectasis. It presents indepth analysis of Bronchiectasis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Bronchiectasis. The report covers a key snapshot of trial trends, enrollme...

2019 Pulmonary Fibrosis Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Pulmonary Fibrosis Clinical Trials Study provides complete list of trials completed, ongoing and planned for Pulmonary Fibrosis. It presents indepth analysis of Pulmonary Fibrosis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Pulmonary Fibrosis. The report covers a key snapshot of trial ...

Diagnosed ovarian cancer cases set to reach 66,000 across seven major markets in 2028, says GlobalData

Ovarian cancer is the most lethal gynaecologic cancer and is currently a leading cause of mortality across the world. The...Read More... The post Diagnosed ovarian cancer cases set to reach 66,000 across seven major markets in 2028, says GlobalData appeared first on Pharmaceutical Technology.

2019 Traumatic Brain Injury Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Traumatic Brain Injury Clinical Trials Study provides complete list of trials completed, ongoing and planned for Traumatic Brain Injury. It presents indepth analysis of Traumatic Brain Injury clinical trials across markets and companies. The research work is for providing complete understanding into trends in Traumatic Brain Injury. The report covers a key sn...

OASMIA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm

New York, New York--(Newsfile Corp. - September 20, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (NASDAQ: OASM) ("Oasmia" or t...

Total prevalent cases of female infertility to decline to 13.4 million in 2028, says GlobalData

Infertility describes a difficulty in becoming pregnant after trying for a period of one year or more. Impaired feduncity is...Read More... The post Total prevalent cases of female infertility to decline to 13.4 million in 2028, says GlobalData appeared first on Pharmaceutical Technology.

2019 Primary Systemic Amyloidosis Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Primary Systemic Amyloidosis Clinical Trials Study provides complete list of trials completed, ongoing and planned for Primary Systemic Amyloidosis. It presents indepth analysis of Primary Systemic Amyloidosis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Primary Systemic Amyloidosis. Th...

Nursing home population in the 7MM, a high risk group for RSV infections, set to grow by 24% to 6.2m people by 2028, says GlobalData

Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus which belongs to the bigger family of Paramyxoviridae....Read More... The post Nursing home population in the 7MM, a high risk group for RSV infections, set to grow by 24% to 6.2m people by 2028, says GlobalData appeared first on Pharmaceutical Technology.

Treatment for dialysis patients with CKD anaemia approved in Japan

A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan. The post Treatment for dialysis patients with CKD anaemia approve

2019 Brain Hemorrhage Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Brain Hemorrhage Clinical Trials Study provides complete list of trials completed, ongoing and planned for Brain Hemorrhage. It presents indepth analysis of Brain Hemorrhage clinical trials across markets and companies. The research work is for providing complete understanding into trends in Brain Hemorrhage. The report covers a key snapshot of trial trends, ...

2019 Hyperalgesia Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Hyperalgesia Clinical Trials Study provides complete list of trials completed, ongoing and planned for Hyperalgesia. It presents indepth analysis of Hyperalgesia clinical trials across markets and companies. The research work is for providing complete understanding into trends in Hyperalgesia. The report covers a key snapshot of trial trends, enrollment trend...

Trump Executive Order Aims to Speed Flu Vaccine Development

The order creates a new task force charged with coming up with a 5-year plan. Medscape Medical News

Two lots of quinacrine recalled due to labelling error

Darmerica LLC is voluntarily recalling two lots of quinacrine dihydrochloride due to a label mix-up. The post Two lots of quinacrine recalled due to labelling error appeared first on European Pharmaceutical Review.

2019 Recurrent Glioblastoma Multiforme GBM Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Recurrent Glioblastoma Multiforme GBM Clinical Trials Study provides complete list of trials completed, ongoing and planned for Recurrent Glioblastoma Multiforme GBM. It presents indepth analysis of Recurrent Glioblastoma Multiforme GBM clinical trials across markets and companies. The research work is for providing complete understanding into trends in Recur...

2019 Recurrent Medulloblastoma Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Recurrent Medulloblastoma Clinical Trials Study provides complete list of trials completed, ongoing and planned for Recurrent Medulloblastoma. It presents indepth analysis of Recurrent Medulloblastoma clinical trials across markets and companies. The research work is for providing complete understanding into trends in Recurrent Medulloblastoma. The report cov...

2019 Sciatica Clinical Trials Guide Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 [Published by VPA Research] Prices from USD $1799

The global clinical trial report 2019 Sciatica Clinical Trials Study provides complete list of trials completed, ongoing and planned for Sciatica. It presents indepth analysis of Sciatica clinical trials across markets and companies. The research work is for providing complete understanding into trends in Sciatica. The report covers a key snapshot of trial trends, enrollment trends, success trend...


Quick Search

News Quicklinks